Association Between Mitochondrial DNA Content and Risk of Gastric Cancer

Overview

Compelling epidemiological evidence indicates that alterations of mitochondrial DNA, including mutations and abnormal content of mitochondrial DNA (mtDNA), are associated with the initiation and development of gastric cancer.The aim of this study was to explore association between mtDNA content in peripheral blood cells could be used as a risk predictor for gastric cancer.

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Retrospective
  • Study Primary Completion Date: September 2016

Arms, Groups and Cohorts

  • Gastric cancer group
    • 300 consecutive patients were recruited, who have diagnosed with gastric cancer by biopsy
  • Control group
    • The 300 healthy controls without previous cancer history were recruited from individuals who visited investigator’s hospital for physical examination during the same time period as the case enrollment.

Clinical Trial Outcome Measures

Primary Measures

  • Relative copy number of mitochondrial DNA
    • Time Frame: From date of percutaneous coronary intervention until the date of discharging from hospital, assessed up to 5 days
    • The ratio of mitochondrial DNA contents to hemoglobin contents was calculated for each sample from standard curves. After that, the ratio for each sample was normalized to a calibrator DNA in order to standardize between different runs, and then defined as the measurement of relative mtDNA contents.Relative expression of mtDNA were measured in patients suffered from gastric cancer when compared with control group.

Participating in This Clinical Trial

Inclusion Criteria

  • 1.histological confirmed gastric adenocarcinoma; 2.receiving surgical resection; 3.no preoperative anticancer treatment; 4.alive at least 1 months after surgery. Exclusion Criteria:

  • 1.history of other malignancy; 2.blood transfusion within one month or prior bone marrow transplantation; 3.patients who reluctant to sign informed consent.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 85 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Air Force Military Medical University, China
  • Provider of Information About this Clinical Study
    • Principal Investigator: Wenyi Guo, Professor of Department of Cardiology of Xijing Hospital – Air Force Military Medical University, China

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.